Thyrocare Technologies Ltd. announces an acquisition

The headline consideration is approximately Rs 141.40 Crores for Thyrocare’s sale of its 100% stake in Nueclear Healthcare Limited. It comprises:

• Rs 81.90 Crores in cash, subject to a working-capital adjustment ^[1]
• Rs 59.50 Crores in Trovera Healthcare CCPS, representing 42,500 shares issued at Rs 14,000 per share ^[2]

Accordingly, the sale appears to value Nueclear at Rs 141.40 Crores, but a reliable premium, discount, or accounting gain/loss versus Thyrocare’s original investment cost or carrying value cannot be calculated without those two balance-sheet inputs. The comparison should also use the value of the investment in the subsidiary, rather than the gross value of Nueclear’s operating assets.

Nueclear’s FY24 contribution cannot be quantified from the available evidence because segment-level revenue and EBITDA for Nueclear Healthcare were not reported in the cited material. Thyrocare’s FY24 consolidated base was:

Accordingly, Nueclear’s share of consolidated revenue and EBITDA, and its standalone EBITDA margin, could not be confirmed. Without those inputs, the post-divestment margin and ROCE impact cannot be calculated reliably.

Expected operating impact

The direction is potentially positive for margins and ROCE, but not quantifiable from the disclosed data:

• Thyrocare described Nueclear’s radiology business as requiring continued investment in equipment, technology, maintenance and infrastructure. ^[8]
• This supports the inference that exiting the business could improve consolidated capital efficiency if Nueclear generated a lower return on capital than the core pathology business.
• Operating margins would improve only if Nueclear’s EBITDA margin was below Thyrocare’s consolidated FY24 margin of 25.70%. If Nueclear was above that level, the mix effect could instead dilute margins.
• ROCE would improve if the capital employed released from Nueclear was large relative to the EBIT being removed. The transaction proceeds are approximately Rs 141.40 Crores, subject to approvals and transaction adjustments. ^[9]
• No quantified management guidance for the post-divestment operating margin or ROCE was reported. Therefore, the defensible conclusion is directionally margin- and ROCE-accretive potential, but no confirmed numerical uplift.

Thyrocare is exiting the radiology/imaging business operationally, but not every asset or economic linkage associated with it. The transaction transfers 100% of Nueclear Healthcare Limited to Trovera; upon completion, Thyrocare will cease to hold equity in Nueclear. The SPA remains subject to customary conditions precedent. ^[1]

What Thyrocare retains

• Real estate: VCCircle reported that Thyrocare will separately purchase Nueclear-held land and buildings in Gurugram and Hyderabad for Rs 20.58 Crores. These are retained property assets, not evidence of a continuing radiology operating business. ^[10]
• Indirect financial exposure: Part of the consideration is 42,500 CCPS of Trovera valued at Rs 59.50 Crores. Since Nueclear will become wholly owned by Trovera, Thyrocare will retain an economic interest through these securities, but not direct ownership of the imaging subsidiary. ^{[1] [11]}
• No retained imaging platform is identified: The cited filing documents do not identify any continuing Thyrocare-owned radiology centres, scanners, or imaging operations after Nueclear is transferred. The precise treatment of individual equipment assets could not be confirmed for the period.

How this fits the 2021 acquisition

The exact strategic rationale stated at the time of the 2021 Nueclear acquisition could not be confirmed from the cited material. The current pivot nevertheless indicates a reversal of the direct-ownership thesis: rather than continuing to fund imaging as an adjacent growth vertical, Thyrocare is monetising the subsidiary and refocusing capital and management attention on pathology. ^[10]

The reported reason is economic rather than regulatory: Nueclear’s radiology business requires continuing investment in equipment, technology, maintenance and infrastructure. ^[8] That makes the transaction consistent with a decision that the capital intensity and operating requirements of imaging do not fit as well with Thyrocare’s core pathology model. Thyrocare is therefore exiting the operating business, while preserving selected real-estate assets and an indirect financial option through Trovera’s CCPS.